About Corsidus

Corsidus provides industry-leading early drug development services including human microdose studies, positron emission tomography imaging studies and a full suite of preclinical tests to pharmaceutical, biotechnology and bio-discovery researchers. Our mission is to provide focused and specific guidance to customers and facilitate rapid progression of discovery compounds from lead selection into preclinical programs and Phase 1 clinical trials.

Corsidus utilizes the ultra-sensitive detection capabilities of accelerator mass spectrometry to assess and characterize the desired properties of drug candidates at the earliest possible stage through human clinical microdose programs. Study requirements for a human microdosing trial including safety, toxicology and pharmacology tests, drug substance supply and radiolabeling of drug candidates are provided by Corsidus.

Corsidus Consulting is a service that provides early drug development expertise to researchers in smaller biopharmaceutical companies and academic research centers and guides them through a custom suite of preclinical tests designed to assess the safety and toxicity profiles of discovery candidates in a rapid and cost-effective manner.

Corsidus Program Management capabilities are focused on coordinating and streamlining early drug development efforts and providing comprehensive regulatory compliance expertise. Corsidus will assist in the design, the management and the implementation of a cost-effective early drug development strategy to meet timelines and scientific objectives within an allocated budget.